On December 4, 2025, Denali Therapeutics Inc. entered into a $275 million synthetic royalty funding agreement with Royalty Pharma, granting a 9.25% royalty on future sales of tividenofusp alfa, an enzyme therapy for Hunter syndrome. Denali retains development rights and is aiming for FDA approval by April 5, 2026.